Drug Approval | November 23, 2022
USFDA grants priority review of BLA for dengue vaccine TAK-003
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
Cadila Pharmaceuticals was felicitated during the plenary session of the 21st International Leprosy Congress
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
Value chain collaboration aims to foster a circular ecosystem and reduce the carbon footprint of single-use surgical instruments molded in Ixef PARA.
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
Esiloc was launched at the biggest doctor engagement webinar involving more than 12,000 doctors across the country
MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae
Subscribe To Our Newsletter & Stay Updated
